Kesios Therapeutics

Kesios Therapeutics, a portfolio company of tech transfer group Imperial Innovations, has appointed Paolo Paoletti as Executive Chairman.

In the past, Paoletti worked as the first President of GSK Oncology, before its sale to Novartis.

He is now a non-executive director of PsiOxus Therapeutics, Imperial Innovations’ sixth largest company, which is developing oncolytic immuno-oncology treatments.

Kesios is developing new therapies for multiple myeloma and other cancers. It is based in South Kensington, London and was created to commercialise research which began in the Department of Medicine at Imperial College London.

Imperial professor Guido Franzoso has identified a novel drug target within a pathway that appears to be critical for promoting cancer cell survival in certain white blood cells of patients with multiple myeloma and other malignancies.

Kesios’ drug candidates disrupt this target and may be able to selectively kill cancer cells without causing toxicity to normal cells.

(Image: Imperial College London)​